R.J.B. Driessen

Extent and Clinical Consequences of Antibody Formation Against Adalimumab in Patients With Plaque Psoriasis

L.L.A. Lecluse, R.J.B. Driessen, Phyllis I. Spuls et al. · Archives of Dermatology · 2010 · 147 citations · Full text

‘Happy’ drug survival of adalimumab, etanercept and ustekinumab in psoriasis in daily practice care: results from the Bio<scp>CAPTURE</scp>network

J. M. P. A. van den Reek, Jeffrey Zweegers, Wietske Kievit et al. · British Journal of Dermatology · 2014 · 97 citations

Three-year registry data on biological treatment for psoriasis: the influence of patient characteristics on treatment outcome

R.J.B. Driessen, J.B.M. Boezeman, P.C.M. van de Kerkhof et al. · British Journal of Dermatology · 2009 · 78 citations

Body mass index predicts discontinuation due to ineffectiveness and female sex predicts discontinuation due to side-effects in patients with psoriasis treated with adalimumab, etanercept or ustekinumab in daily practice: a prospective, comparative, long-t

Jeffrey Zweegers, J.M.P.A. van den Reek, P.C.M. van de Kerkhof et al. · British Journal of Dermatology · 2016 · 78 citations

Etanercept combined with methotrexate for high-need psoriasis

R.J.B. Driessen, P.C.M. van de Kerkhof, E.M.G.J. de Jong · British Journal of Dermatology · 2008 · 68 citations · Full text